Moxonidine has been shown to selectively interact with I1-imidazoline receptors within the brainstem. These imidazoline-sensitive receptors are concentrated in the rostral ventrolateral medulla, an area critical to the central control of the peripheral sympathetic nervous system. The net effect of this interaction with the I1-imidazoline receptor appears to result in a reduced activity of sympathetic nerves (demonstrated for cardiac, splanchnic and renal sympathetic nerves). Moxonidine leads to a reduction of systemic vascular resistance and consequently in arterial blood pressure.
The usual adult starting dose is 0.2mg moxonidine, the tablets may be taken before, during or after the meal. Once daily.
Hypersensitivity to the active substance of the product,history of angioneurotic oedema, sick sinus syndrome or sino-atrial block, 2 and 3-degree atrioventricular block, bradycardia,malignant arrhythmia, cardiac insufficiency,severe coronary heart disease or unstable angina pectoris, severe hepatic insufficiency, severe renal insufficiency
Cases of varying degrees of AV block,severe coronary artery disease or unstable angina pectoris and renal impairment
There are no adequate data for theuse of moxonidine in pregnant women, Moxonidine should not be used during lactation,Moxonidine should not be given to children and adolescents under 16 years of age,
Concomitant administration of moxonidine and other antihypertensive agents result in an additive effect,Tricyclic antidepressants may reduce the effectiveness, can potentiate the sedative effect of tricyclic anti-depressants, so avoid co-administration,Moxonidine moderately augmented the impaired performance in cognitive functions in subjects receiving lorazepam,sedative effect of benzodiazepines when administered concomitantly.
The most common adverse events for moxonidine include dry mouth, dizziness, asthenia, somnolence, nausea, diarrhea and vomiting.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS